Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

This study is testing epcoritamab — an immunotherapy drug that helps the immune system target cancer cells — as a consolidation treatment (given after initial treatment to keep the cancer away) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). **You may be eligible if:** - You have been diagnosed with CLL or SLL - You received a second-generation BTK inhibitor (acalabrutinib or zanubrutinib), with or without obinutuzumab, for at least 12 months as your first treatment - You achieved at least a partial response to that treatment - You meet established diagnostic criteria for CLL/SLL **You may NOT be eligible if:** - You have not completed at least 12 months of first-line BTK inhibitor therapy - Your disease did not respond to prior treatment - You have significant health conditions that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.